Kenya: More Funding Needed for TB-HIV Co-Infection
[Key Correspondents]HIV and tuberculosis advocates say failure by donors and governments to invest more in these diseases may thwart efforts to end both epidemics resulting in thousands of preventable deaths.
[WHO] The World Health Organization and the Global Fund to Fight AIDS, Tuberculosis and Malaria signed a cooperation and financing agreement to implement 10 strategic initiatives to accelerate the end of AIDS, tuberculosis and malaria as epidemics and strengthen systems for health. This new agreement, which will cover the 2021-2023 implementation period, aims to address some of the persistent challenges that impede progress against the three diseases and protect hard-won gains from new pandemics like COVID-19.
[Global Fund] Ouagadougou -- Burkina Faso and the Global Fund strengthened their partnership by launching four new grants that move toward ending epidemics of HIV, tuberculosis, malaria and strengthen health systems with a focus on community health systems and data quality.
[MSF] As the number of people with COVID-19 grows daily, Eswatini is now battling yet another health crisis on top of existing epidemics of HIV and tuberculosis (TB)
[MSF] eSwatini has the highest percentage of people living with HIV in the world. Almost one-thirds of adults are HIV-positive. The country is also severely affected by a tuberculosis (TB) epidemic and around 70 percent of all TB patients are co-infected with HIV. 
[The Conversation Africa] Tuberculosis (TB) and HIV pose a significant burden on South Africa's health system. There's a close relationship between the two. About 60% of TB patients are also HIV-positive. The novel coronavirus (Sars-CoV-2) is likely to be of particular concern for communities with high rates of TB and HIV. Sars-CoV-2 and its resulting disease (COVID-19) haven't been fully researched and understood yet. But speculation based on the behaviour of other viruses and chronic illnesses raises concerns that HIV and TB pati
[The Conversation Africa] The infectious disease burden in Africa is very high, particularly for tuberculosis (TB), malaria and HIV/AIDS. In 2018, nearly a quarter (24%) of TB cases in the world were in Africa. The region accounted for 93% of malaria cases. The continent also bears the brunt of the HIV epidemic: 20.6 million of the 37.9 million people living with HIV are in eastern and southern Africa.
[Premium Times] The Nigerian government has pledged to release $12 million to end epidemics of HIV/AIDS, tuberculosis, malaria and other preventable and treatable disease across the globe.
[Global Fund] Lyon, France -In an unprecedented show of global solidarity, donors at the Global Fund's Sixth Replenishment Conference pledged US$14.02 billion for the next three years - the largest amount ever raised for a multilateral health organization, and the largest amount by the Global Fund. The funds will help save 16 million lives and end the epidemics of AIDS, tuberculosis and malaria by 2030.
In conclusion, our findings demonstrate that in the presence of an HIV-1 infection, the cellular distribution of FcγRIIIa is altered and that the functional consequence of FcγRIIIa variant is affected. Importantly, it underscores the need to characterize FcγR expression, cellular distribution and functional consequences of FcγR genetic variants within a specific environment or disease state. Introduction Receptors for the Fc domain of immunoglobulin G (IgG), so called Fc gamma receptors (FcγRs), link the specificity of IgG with potent effector functions of the innate immune system. Fc&ga...
In this study, we investigated the immunological changes in the levels of monocytes and Tregs and the associations between these cell types in HIV-1-infected MSM with syphilis. Methods Study Participants We enrolled 81 participants in this study. These individuals were assigned to four groups on the basis of serologic testing and HIV-1 results, namely, the rapid plasma reagin (RPR+) group, the CHI group, the CHI&RPR+ group, and the healthy control group. HIV-1 infection status was determined with the HIV-1/2 antigen/antibody combo enzyme immunoassay (Beijing Wantai Biological Medical Company, Beijing, China). Positive ...